The Schedule 13D filed with the Securities and Exchange Commission on March 16, 2018 (as previously
amended, the “Schedule 13D”) by (i) L-5 Healthcare Partners, LLC, a Delaware limited liability company (“L-5”), and (ii) Paul
Segal, an individual with United States citizenship (collectively, the “Reporting Persons”), with respect to the common stock, par value $0.0001 per share (the “Common Stock”), of Alphatec Holdings, Inc., a Delaware
corporation (the “Issuer”), is hereby amended to furnish the additional information set forth herein. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule
13D.
Item 3. Source and Amount of Funds or Other Consideration.
Item 3 of the Schedule 13D is hereby supplemented by adding the following at the end thereof:
Pursuant to an order entered by the Delaware Chancery Court on September 27, 2024, the Issuer was required to offer to
L-5, the right to purchase from the Issuer a warrant to purchase up to 1,133,160 shares of Common Stock at an exercise price of $2.17 per share (the “Warrant”). On November 8, 2024, L-5 purchased the Warrant from the Issuer. The purchase price of the Warrant was $1.98 per share, for a total purchase price of approximately $2.2 million. The Warrant expires on June 21, 2026.
Item 5. Interest in Securities of the Issuer.
Item
5 of the Schedule 13D is hereby amended and restated as follows:
(a) and (b) The information contained on the cover pages to this Schedule 13D and
Item 3 is incorporated herein by reference
The aggregate percentage of Common Stock reported owned by each person named herein is based upon 141,767,870
shares of Common Stock outstanding as of October 24, 2024, which is the total number of shares of Common Stock outstanding as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on October 30, 2024, together with 1,133,160 shares of Common Stock issuable upon the exercise of a warrant of the Issuer.
L-5 directly holds 10,614,698 shares of Common Stock (which includes 9,481,538 shares of Common Stock and 1,133,160
shares of Common Stock issuable upon the exercise of a warrant of the Issuer) reported in this Schedule 13D. As a result of his relationship with L-5, Paul Segal may be deemed the beneficial owner of all such
shares of Common Stock. Mr. Segal, however, disclaims beneficial ownership of such shares, except to the extent of his indirect pecuniary interest therein.
(c) In addition to the transaction set forth in Item 3 above, transaction in the Common Stock effected by the Reporting Persons in the last sixty
(60) days are set forth on Exhibit 1 to this amendment..
(d) Not applicable.
(e) Not applicable.
Item 7. Material to Be Filed as
Exhibits
|
|
|
| Exhibit No. |
|
Description |
|
|
| Exhibit 1 |
|
Schedule of Transactions for Item 5(c) of Amendment No. 7. |